A series of Benzimidazole derivatives were obtained via reaction of 2-chloro-1H-benzo[d]imidazole (1) with morpholine, which produce benzo[d]imidazol-yl-morpholine 2 that react with chloroacetonitrile to give (benzo[d]imidazol-yl)acetonitrile 3, by its next reaction with hydrazine hydrate afforded the key intermediate 4, that afford thiadiazole derivatives 5 by its reaction with carbon disulfide via cyclization reaction. Alkylation of compound 5 with ethyl bromoacetate, afforded benzo[d]imidazolo derivative 6, that react with thioglycolic acid to give thiazolidine compound in suitable conditions. Also Benzimidazole 1 reacted with various Wittig Horner reagents in DMF to afford phosphoryl and phosphonates derivatives 12a-e in moderate yields. On the other hand, 1 react with trialkyl phosphites to yield the known phosphonates derivatives 14a-c in high yields, also we obtained the same products by reacting 1 with dialkyl phosphites. In addition, hexaalkyltriamidophosphites were applied to 1 in ethanol to afford phosphonic diamide derivatives 17a-c in high yields through addition-elimination reaction. Antitumor activity of the newly synthesized compounds were tested on three cell lines of breast (MCF7) and liver (HepG2) carcinoma cell lines and HCT-116 cancer cells together with human healthy cell line (BJ-1) using the MTT assay. Most compounds suppressed three cancer cells (HCT-116, HepG2 and MCF-7) and exhibited considerable anticancer properties in a dose-dependent manner
No takes yet. Share an insight, caveat, or question.
Sabry et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: